NASDAQ:ACRS

Aclaris Therapeutics Competitors

$28.96
-0.13 (-0.45 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.60
Now: $28.96
$29.64
50-Day Range
$20.67
MA: $23.97
$29.60
52-Week Range
$1.02
Now: $28.96
$30.38
Volume416,129 shs
Average Volume2.81 million shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

Aclaris Therapeutics (NASDAQ:ACRS) Vs. IONS, SRPT, ALLK, BPMC, PRGO, and SDGR

Should you be buying ACRS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aclaris Therapeutics, including Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), and Schrödinger (SDGR).

Ionis Pharmaceuticals (NASDAQ:IONS) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ionis Pharmaceuticals and Aclaris Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.31$303.26 million$2.0820.37
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87

Ionis Pharmaceuticals has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
Aclaris Therapeutics-941.07%-104.00%-64.47%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ionis Pharmaceuticals and Aclaris Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
Aclaris Therapeutics0000N/A

Ionis Pharmaceuticals presently has a consensus price target of $57.9091, suggesting a potential upside of 36.71%. Given Ionis Pharmaceuticals' higher probable upside, equities analysts plainly believe Ionis Pharmaceuticals is more favorable than Aclaris Therapeutics.

Institutional & Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats Aclaris Therapeutics on 11 of the 13 factors compared between the two stocks.

Aclaris Therapeutics (NASDAQ:ACRS) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Profitability

This table compares Aclaris Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aclaris Therapeutics-941.07%-104.00%-64.47%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Aclaris Therapeutics and Sarepta Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aclaris Therapeutics0000N/A
Sarepta Therapeutics191202.50

Sarepta Therapeutics has a consensus price target of $150.4762, suggesting a potential upside of 113.32%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Aclaris Therapeutics.

Earnings & Valuation

This table compares Aclaris Therapeutics and Sarepta Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87
Sarepta Therapeutics$380.83 million14.71$-715,080,000.00($9.71)-7.26

Aclaris Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aclaris Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Insider and Institutional Ownership

59.1% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 8.2% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sarepta Therapeutics beats Aclaris Therapeutics on 9 of the 13 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Allakos and Aclaris Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Aclaris Therapeutics0000N/A

Allakos presently has a consensus target price of $181.50, indicating a potential upside of 72.86%. Given Allakos' higher possible upside, equities research analysts clearly believe Allakos is more favorable than Aclaris Therapeutics.

Volatility & Risk

Allakos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Comparatively, 8.2% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Allakos and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Aclaris Therapeutics-941.07%-104.00%-64.47%

Valuation and Earnings

This table compares Allakos and Aclaris Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-55.56
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87

Allakos has higher earnings, but lower revenue than Aclaris Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Allakos beats Aclaris Therapeutics on 9 of the 12 factors compared between the two stocks.

Aclaris Therapeutics (NASDAQ:ACRS) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Aclaris Therapeutics and Blueprint Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aclaris Therapeutics0000N/A
Blueprint Medicines06712.64

Blueprint Medicines has a consensus target price of $111.00, indicating a potential upside of 17.88%. Given Blueprint Medicines' higher probable upside, analysts clearly believe Blueprint Medicines is more favorable than Aclaris Therapeutics.

Volatility and Risk

Aclaris Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Aclaris Therapeutics and Blueprint Medicines' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87
Blueprint Medicines$66.51 million82.05$-347,690,000.00($7.27)-12.95

Aclaris Therapeutics has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aclaris Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aclaris Therapeutics-941.07%-104.00%-64.47%
Blueprint Medicines41.08%43.72%33.35%

Insider and Institutional Ownership

59.1% of Aclaris Therapeutics shares are held by institutional investors. 8.2% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 3.8% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Blueprint Medicines beats Aclaris Therapeutics on 8 of the 14 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Earnings and Valuation

This table compares Perrigo and Aclaris Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.12$146.10 million$4.0310.06
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87

Perrigo has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are owned by institutional investors. 0.3% of Perrigo shares are owned by insiders. Comparatively, 8.2% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Perrigo and Aclaris Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Aclaris Therapeutics0000N/A

Perrigo presently has a consensus price target of $52.00, indicating a potential upside of 28.30%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Aclaris Therapeutics.

Volatility and Risk

Perrigo has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Perrigo and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Aclaris Therapeutics-941.07%-104.00%-64.47%

Summary

Perrigo beats Aclaris Therapeutics on 9 of the 13 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Schrödinger and Aclaris Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.48$-24,570,000.00N/AN/A
Aclaris Therapeutics$4.23 million354.67$-161,350,000.00($2.25)-12.87

Schrödinger has higher revenue and earnings than Aclaris Therapeutics.

Institutional and Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are held by institutional investors. 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Schrödinger and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Aclaris Therapeutics-941.07%-104.00%-64.47%

Analyst Ratings

This is a summary of current ratings and price targets for Schrödinger and Aclaris Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Aclaris Therapeutics0000N/A

Schrödinger presently has a consensus target price of $85.50, suggesting a potential upside of 15.70%. Given Schrödinger's higher possible upside, analysts plainly believe Schrödinger is more favorable than Aclaris Therapeutics.

Summary

Schrödinger beats Aclaris Therapeutics on 7 of the 10 factors compared between the two stocks.


Aclaris Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.